{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:39:20Z","timestamp":1792147160203,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40257-023-00788-2","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T04:02:26Z","timestamp":1685073746000},"page":"837-847","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study"],"prefix":"10.1007","volume":"24","clinical-trial-number":[{"clinical-trial-number":"nct04057937","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0275-4311","authenticated-orcid":false,"given":"Tadashi","family":"Terui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9526-1259","authenticated-orcid":false,"given":"Yukari","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigetoshi","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-3754","authenticated-orcid":false,"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3743-135X","authenticated-orcid":false,"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Yaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuka","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Handa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamoto","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"issue":"1","key":"788_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jdermsci.2020.03.003","volume":"98","author":"M Murakami","year":"2020","unstructured":"Murakami M, Terui T. Palmoplantar pustulosis: current understanding of disease definition and pathomechanism. J Dermatol Sci. 2020;98(1):13\u20139.","journal-title":"J Dermatol Sci"},{"issue":"3","key":"788_CR2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40257-020-00503-5","volume":"21","author":"M Misiak-Galazka","year":"2020","unstructured":"Misiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar pustulosis: recent advances in etiopathogenesis and emerging treatments. Am J Clin Dermatol. 2020;21(3):355\u201370.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"788_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/1346-8138.14850","volume":"46","author":"K Masuda-Kuroki","year":"2019","unstructured":"Masuda-Kuroki K, Murakami M, Kishibe M, Kobayashi S, Okubo Y, Yamamoto T, et al. Diagnostic histopathological features distinguishing palmoplantar pustulosis from pompholyx. J Dermatol. 2019;46(5):399\u2013408.","journal-title":"J Dermatol"},{"issue":"10","key":"788_CR4","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/j.1600-0625.2011.01325.x","volume":"20","author":"M Murakami","year":"2011","unstructured":"Murakami M, Hagforsen E, Morhenn V, Ishida-Yamamoto A, Iizuka H. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol. 2011;20(10):845\u20137.","journal-title":"Exp Dermatol"},{"issue":"4","key":"788_CR5","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jaci.2016.10.021","volume":"139","author":"Y Liang","year":"2017","unstructured":"Liang Y, Xing X, Beamer MA, Swindell WR, Sarkar MK, Roberts LW, et al. Six-transmembrane epithelial antigens of the prostate comprise a novel inflammatory nexus in patients with pustular skin disorders. J Allergy Clin Immunol. 2017;139(4):1217\u201327.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"788_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006450","volume":"5","author":"K Kubota","year":"2015","unstructured":"Kubota K, Kamijima Y, Sato T, Ooba N, Koide D, Iizuka H, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015;5(1): e006450.","journal-title":"BMJ Open"},{"key":"788_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011628.pub2","author":"G Obeid","year":"2020","unstructured":"Obeid G, Do G, Kirby L, Hughes C, Sbidian E, Le Cleach L. Interventions for chronic palmoplantar pustulosis. Cochrane Database Sys Rev. 2020. https:\/\/doi.org\/10.1002\/14651858.CD011628.pub2.","journal-title":"Cochrane Database Sys Rev."},{"issue":"11","key":"788_CR8","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamadermatol.2020.3275","volume":"156","author":"N Benzian-Olsson","year":"2020","unstructured":"Benzian-Olsson N, Dand N, Chaloner C, Bata-Csorgo Z, Borroni R, Burden AD, et al. Association of clinical and demographic factors with the severity of palmoplantar pustulosis. JAMA Dermatol. 2020;156(11):1216\u201322.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"788_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jdermsci.2022.03.001","volume":"106","author":"K Masuda-Kuroki","year":"2022","unstructured":"Masuda-Kuroki K, Kawakami H, Abe N, Mori M, Tobita R, Fukushi R, et al. Nail lesions in palmoplantar pustulosis and pustulotic arthro-osteitis impairs patients\u2019 quality of life: suggesting new assessment tool of PPP nail lesions. J Dermatol Sci. 2022;106(1):29\u201336.","journal-title":"J Dermatol Sci"},{"issue":"10","key":"788_CR10","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1111\/jdv.14187","volume":"31","author":"H Trattner","year":"2017","unstructured":"Trattner H, Bl\u00fcml S, Steiner I, Plut U, Radakovic S, Tanew A. Quality of life and comorbidities in palmoplantar pustulosis\u2014a cross-sectional study on 102 patients. J Eur Acad Dermatol Venereol. 2017;31(10):1681\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"788_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155215","volume":"11","author":"R Bissonnette","year":"2016","unstructured":"Bissonnette R, Su\u00e1rez-Fari\u00f1as M, Li X, Bonifacio KM, Brodmerkel C, Fuentes-Duculan J, et al. Based on molecular profiling of gene expression, palmoplantar pustulosis and palmoplantar pustular psoriasis are highly related diseases that appear to be distinct from psoriasis vulgaris. PLoS ONE. 2016;11(5): e0155215.","journal-title":"PLoS ONE"},{"issue":"6","key":"788_CR12","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/1346-8138.15826","volume":"48","author":"T Yamamoto","year":"2021","unstructured":"Yamamoto T. Similarity and difference between palmoplantar pustulosis and pustular psoriasis. J Dermatol. 2021;48(6):750\u201360.","journal-title":"J Dermatol"},{"issue":"3","key":"788_CR13","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jaci.2018.06.038","volume":"143","author":"S Twelves","year":"2019","unstructured":"Twelves S, Mostafa A, Dand N, Burri E, Farkas K, Wilson R, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019;143(3):1021\u20136.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"788_CR14","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/1346-8138.13064","volume":"43","author":"Y Umezawa","year":"2016","unstructured":"Umezawa Y, Nakagawa H, Tamaki K. Phase III clinical study of maxacalcitol ointment in patients with palmoplantar pustulosis: a randomized, double-blind, placebo-controlled trial. J Dermatol. 2016;43(3):288\u201393.","journal-title":"J Dermatol"},{"issue":"1","key":"788_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3109\/09546634.2015.1052036","volume":"27","author":"M Muro","year":"2016","unstructured":"Muro M, Kawakami H, Matsumoto Y, Abe N, Tsuboi R, Okubo Y. Topical combination therapy with vitamin D3 and corticosteroid ointment for palmoplantar pustulosis: a prospective, randomized, left-right comparison study. J Dermatol Treat. 2016;27(1):51\u20133.","journal-title":"J Dermatol Treat"},{"issue":"6","key":"788_CR16","first-page":"758","volume":"20","author":"K Hayama","year":"2010","unstructured":"Hayama K, Inadomi T, Fujisawa D, Terui T. A pilot study of medium-dose cyclosporine for the treatment of palmoplantar pustulosis complicated with pustulotic arthro-osteitis. Eur J Dermatol. 2010;20(6):758\u201362.","journal-title":"Eur J Dermatol"},{"issue":"3","key":"788_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jamadermatol.2017.5937","volume":"154","author":"T Terui","year":"2018","unstructured":"Terui T, Kobayashi S, Okubo Y, Murakami M, Hirose K, Kubo H. Efficacy and safety of guselkumab, an anti-interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial. JAMA Dermatol. 2018;154(3):309\u201316.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"788_CR18","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1111\/1346-8138.16132","volume":"48","author":"Y Okubo","year":"2021","unstructured":"Okubo Y, Morishima H, Zheng R, Terui T. Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study. J Dermatol. 2021;48(12):1838\u201353.","journal-title":"J Dermatol"},{"issue":"2","key":"788_CR19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/1346-8138.14717","volume":"46","author":"H Kawakami","year":"2019","unstructured":"Kawakami H, Nagaoka Y, Hirano H, Matsumoto Y, Abe N, Tsuboi R, et al. Evaluation of the efficacy of granulocyte and monocyte adsorption apheresis on skin manifestation and joint symptoms of patients with pustulotic arthro-osteitis. J Dermatol. 2019;46(2):144\u20138.","journal-title":"J Dermatol"},{"issue":"6","key":"788_CR20","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al. Treatment of psoriatic arthritis in a phase 3 randomized, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"788_CR21","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.3899\/jrheum.151376","volume":"43","author":"M Cutolo","year":"2016","unstructured":"Cutolo M, Myerson GE, Fleischmann R, Liote F, Diaz-Gonzalez F, Van den Bosch F, et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016;43(9):1724\u201334.","journal-title":"J Rheumatol"},{"issue":"6","key":"788_CR22","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","volume":"75","author":"CJ Edwards","year":"2016","unstructured":"Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75(6):1065\u201373.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"788_CR23","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","volume":"57","author":"AF Wells","year":"2018","unstructured":"Wells AF, Edwards CJ, Kivitz AJ, Bird P, Nguyen D, Paris M, et al. Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. Rheumatology. 2018;57(7):1253\u201363.","journal-title":"Rheumatology"},{"issue":"1","key":"788_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM 1]). J Am Acad Dermatol. 2015;73(1):37\u201349.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"788_CR25","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387\u201399.","journal-title":"Br J Dermatol"},{"issue":"2","key":"788_CR26","first-page":"221","volume":"17","author":"L Stein Gold","year":"2018","unstructured":"Stein Gold L, Bagel J, Lebwohl M, Jackson JM, Chen R, Goncalves J, et al. Efficacy and safety of apremilast in systemic- and biologic-naive patients with moderate plaque psoriasis: 52-week results of UNVEIL. J Drugs Dermatol. 2018;17(2):221\u20138.","journal-title":"J Drugs Dermatol"},{"key":"788_CR27","doi-asserted-by":"crossref","unstructured":"Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson JM, Chen R, et al. Efficacy and safety of apremilast in patients with moderate plaque psoriasis (UNVEIL phase IV study) [poster 4892]. Annual Meeting of the American Academy of Dermatology; March 3\u20137, 2017; Orlando, FL.","DOI":"10.25251\/skin.1.supp.10"},{"issue":"20","key":"788_CR28","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","volume":"381","author":"G Hatemi","year":"2019","unstructured":"Hatemi G, Mahr A, Ishigatsubo Y, Song YW, Takeno M, Kim D, et al. Trial of apremilast for oral ulcers of Beh\u00e7et\u2019s syndrome. N Engl J Med. 2019;381(20):1918\u201328.","journal-title":"N Engl J Med"},{"key":"788_CR29","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/906349","volume":"2015","author":"PH Schafer","year":"2015","unstructured":"Schafer PH, Chen P, Fang L, Wang A, Chopra R. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1). J Immunol Res. 2015;2015: 906349.","journal-title":"J Immunol Res"},{"issue":"4","key":"788_CR30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/030097402320318387","volume":"31","author":"K Hamzaoui","year":"2002","unstructured":"Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Beh\u00e7et\u2019s disease patients: relationship with disease activity. Scand J Rheumatol. 2002;31(4):205\u201310.","journal-title":"Scand J Rheumatol"},{"issue":"11","key":"788_CR31","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/j.1468-3083.2009.03296.x","volume":"23","author":"T Yamamoto","year":"2009","unstructured":"Yamamoto T. Extra-palmoplantar lesions associated with palmoplantar pustulosis. J Eur Acad Dermatol Venereol. 2009;23(11):1227\u201332.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"788_CR32","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/1744-9987.12210","volume":"18","author":"T Fujisawa","year":"2014","unstructured":"Fujisawa T, Tawada C, Mizutani Y, Doi T, Yoshida S, Ogura S, et al. Efficacy of granulocyte and monocyte adsorption apheresis for treatment of palmoplantar pustulosis. Ther Apher Dial. 2014;18(3):238\u201343.","journal-title":"Ther Apher Dial"},{"issue":"1","key":"788_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MK Basra","year":"2015","unstructured":"Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27\u201333.","journal-title":"Dermatology"},{"issue":"15","key":"788_CR34","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.3390\/molecules27154964","volume":"27","author":"L Crocetti","year":"2022","unstructured":"Crocetti L, Floresta G, Cilibrizzi A, Giovannoni MP. An overview of PDE4 inhibitors in clinical trials: 2010 to early 2022. Molecules. 2022;27(15):4964.","journal-title":"Molecules"},{"key":"788_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2019.09.00","author":"B Strober","year":"2019","unstructured":"Strober B, Alikhan A, Lockshin B, Shi R, Cirulli J, Schafer P. Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: pharmacodynamic results from the UNVEIL study. J Dermatol Sci. 2019. https:\/\/doi.org\/10.1016\/j.jdermsci.2019.09.00.","journal-title":"J Dermatol Sci"},{"issue":"3","key":"788_CR36","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.jaci.2018.05.039","volume":"142","author":"S Garcet","year":"2018","unstructured":"Garcet S, Nograles K, Correa da Rosa J, Schafer PH, Krueger JG. Synergistic cytokine effects as apremilast response predictors in patients with psoriasis. J Allergy Clin Immunol. 2018;142(3):1010-3.e6.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"788_CR37","doi-asserted-by":"publisher","first-page":"669","DOI":"10.4049\/jimmunol.181.1.669","volume":"181","author":"L Skov","year":"2008","unstructured":"Skov L, Beurskens FJ, Zachariae CO, Reitamo S, Teeling J, Satijn D, et al. IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J Immunol. 2008;181(1):669\u201379.","journal-title":"J Immunol"},{"issue":"15","key":"788_CR38","doi-asserted-by":"publisher","first-page":"8261","DOI":"10.3390\/ijms23158261","volume":"23","author":"T Fukasawa","year":"2022","unstructured":"Fukasawa T, Yoshizaki-Ogawa A, Enomoto A, Miyagawa K, Sato S, Yoshizaki A. Involvement of molecular mechanisms between T\/B cells and IL-23: from palmoplantar pustulosis to autoimmune diseases. Int J Mol Sci. 2022;23(15):8261.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"788_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110677","volume":"9","author":"M Murakami","year":"2014","unstructured":"Murakami M, Kaneko T, Nakatsuji T, Kameda K, Okazaki H, Dai X, et al. Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis. PLoS ONE. 2014;9(10): e110677.","journal-title":"PLoS ONE"},{"issue":"8","key":"788_CR40","first-page":"835","volume":"17","author":"C Pincelli","year":"2018","unstructured":"Pincelli C, Schafer PH, French LE, Augustin M, Krueger JG. Mechanisms underlying the clinical effects of apremilast for psoriasis. J Drugs Dermatol. 2018;17(8):835\u201340.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"788_CR41","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaad.2019.01.066","volume":"80","author":"U Mrowietz","year":"2019","unstructured":"Mrowietz U, Bachelez H, Burden AD, Rissler M, Sieder C, Orsenigo R, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J Am Acad Dermatol. 2019;80(5):1344\u201352.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"788_CR42","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/jamadermatol.2019.1394","volume":"155","author":"T Terui","year":"2019","unstructured":"Terui T, Kobayashi S, Okubo Y, Murakami M, Zheng R, Morishima H, et al. Efficacy and safety of guselkumab in Japanese patients with palmoplantar pustulosis: a phase 3 randomized clinical trial. JAMA Dermatol. 2019;155(10):1153\u201361.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"788_CR43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1517\/14740338.4.1.129","volume":"4","author":"J Van Zander","year":"2005","unstructured":"Van Zander J, Orlow SJ. Efficacy and safety of oral retinoids in psoriasis. Expert Opin Drug Saf. 2005;4(1):129\u201338.","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"788_CR44","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1001\/archderm.1993.01680310043006","volume":"129","author":"S Reitamo","year":"1993","unstructured":"Reitamo S, Erkko P, Remitz A, Lauerma AI, Montonen O, Harjula K. Cyclosporine in the treatment of palmoplantar pustulosis. A randomized, double-blind, placebo-controlled study. Arch Dermatol. 1993;129(10):1273\u20139.","journal-title":"Arch Dermatol"},{"issue":"6","key":"788_CR45","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1046\/j.1365-2133.1998.02555.x","volume":"139","author":"P Erkko","year":"1998","unstructured":"Erkko P, Granlund H, Remitz A, Rosen K, Mobacken H, Lindel\u00f6f B, et al. Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis. Br J Dermatol. 1998;139(6):997\u20131004.","journal-title":"Br J Dermatol"},{"issue":"11","key":"788_CR46","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/1346-8138.14523","volume":"45","author":"H Fujita","year":"2018","unstructured":"Fujita H, Terui T, Hayama K, Akiyama M, Ikeda S, Mabuchi T, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235\u201370.","journal-title":"J Dermatol"},{"issue":"6","key":"788_CR47","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1111\/bjd.17587","volume":"180","author":"J Berth-Jones","year":"2019","unstructured":"Berth-Jones J, Exton LS, Ladoyanni E, Mohd Mustapa MF, Tebbs VM, Yesudian PD, et al. British Association of Dermatologists guidelines for the safe and effective prescribing of oral ciclosporin in dermatology 2018. Br J Dermatol. 2019;180(6):1312\u201338.","journal-title":"Br J Dermatol"},{"issue":"5","key":"788_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153740","volume":"11","author":"J West","year":"2016","unstructured":"West J, Ogston S, Foerster J. Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials. PLoS ONE. 2016;11(5): e0153740.","journal-title":"PLoS ONE"},{"issue":"5","key":"788_CR49","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/ijd.15382","volume":"60","author":"N Kato","year":"2021","unstructured":"Kato N, Takama H, Ando Y, Yanagishita T, Ohshima Y, Ohashi W, et al. Immediate response to apremilast in patients with palmoplantar pustulosis: a retrospective pilot study. Int J Dermatol. 2021;60(5):570\u20138.","journal-title":"Int J Dermatol"},{"key":"788_CR50","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2147\/CCID.S240607","volume":"13","author":"E Freitas","year":"2020","unstructured":"Freitas E, Rodrigues MA, Torres T. Diagnosis, screening and treatment of patients with palmoplantar pustulosis (PPP): a review of current practices and recommendations. Clin Cosmet Investig Dermatol. 2020;13:561\u201378.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"10","key":"788_CR51","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1111\/jdv.17441","volume":"35","author":"D Wilsmann-Theis","year":"2021","unstructured":"Wilsmann-Theis D, Kromer C, Gerdes S, Linker C, Magnolo N, Sabat R, et al. A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS). J Eur Acad Dermatol Venereol. 2021;35(10):2045\u201350.","journal-title":"J Eur Acad Dermatol Venereol"}],"updated-by":[{"DOI":"10.1007\/s40257-023-00825-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000}}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00788-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-023-00788-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00788-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T10:36:36Z","timestamp":1704191796000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-023-00788-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["788"],"URL":"https:\/\/doi.org\/10.1007\/s40257-023-00788-2","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]},"assertion":[{"value":"19 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40257-023-00825-0","URL":"https:\/\/doi.org\/10.1007\/s40257-023-00825-0","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Amgen Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Tadashi Terui has received research grants, consulting fees, and\/or speaker\u2019s fees from AbbVie, Amgen, Boehringer Ingelheim, Eli Lilly, Eisai, Kyowa Hakko Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe, Novartis, and Taiho Pharmaceutical. Yukari Okubo has received grants or contracts from AbbVie, Eisai, Jimro, Maruho, Shiseido, Sun Pharma, and Torii; consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eisai, Eli Lilly, Janssen Pharma, Kyowa Kirin, LEO Pharma, Maruho, Pfizer, Sun Pharma, and UCB Pharma; and honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eisai, Eli Lilly, Janssen Pharma, JIMRO, Kyowa Kirin, LEO Pharma, Maruho, Novartis Pharma, Pfizer, Sanofi, Sun Pharma, Taiho, Tanabe-Mitsubishi, Torii and UCB Pharma. Satomi Kobayashi has received research grants from Kyowa Kirin; received honoraria from AbbVie, Eli Lilly, Janssen Pharma, Maruho Pharmaceutical, Novartis, and Taiho Pharmaceutical; and participated in clinical trials for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen Pharma, Kyowa Kirin, Maruho Pharmaceutical, and Pfizer. Shigetoshi Sano has received research grants from Kaken, Maruho, Nihon, Nippon Zoki, Sanofi, Taiho, and Torii; and honoraria from AbbVie, Eisai, Eli Lilly, Janssen Pharma, Kyowa Kirin, Maruho, Sun Pharma, Taiho, and UCB. Akimichi Morita has received research grants, consulting fees, and\/or speaker\u2019s fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Eisai, Janssen, Kyowa Hakko Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe, Nichi-Iko, Nippon Kayaku, Novartis, Pfizer, Sun Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, Ushio, and UCB Pharma. Shinichi Imafuku has received grants and\/or personal fees from AbbVie, Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Eisai, Eli Lilly, GSK, Janssen, Kyowa Kirin, LEO Pharma, Maruho, Novartis, Sun Pharma, Taiho Pharmaceutical, Tanabe-Mitsubishi, Torii Pharmaceutical, and UCB Japan. Yayoi Tada has received honoraria and\/or grants from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb KK, Celgene, Eisai, Eli Lilly, Janssen, Kyowa Kirin, LEO Pharma, Maruho, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Novartis Pharma, Sun Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB Pharma. Masatoshi Abe has received research grants, consulting fees, speaker fees, and\/or participated in clinical trials for Celgene and Maruho. Masafumi Yaguchi, Natsuka Uehara, Takahiro Handa, and Masayuki Tanaka are employees of Amgen K.K. Wendy Zhang and Maria Paris are employees and stockholders of Amgen Inc. Masamoto Murakami has received research grants from AbbVie, ARISTEA Therapeutics, Eisai, Eli Lilly, Kyowa Kirin, and Novartis Pharma; honoraria from AbbVie, Amgen Inc., Boehringer Ingelheim, Celgene, Eisai, Eli Lilly, Janssen Pharma, Kyowa Kirin, Maruho, Novartis Pharma, Taiho Pharmaceutical, and Torii Pharmaceutical; and participated in clinical trials for AbbVie, Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen Pharma, Maruho, and Novartis Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was conducted in accordance with International Council for Harmonisation E6 and the ethical principles that are outlined in the Declaration of Helsinki. The study protocol and all amendments, the informed consent form, and any accompanying materials provided to the patients were reviewed and approved by an institutional review board or independent ethics committee at each study center.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patients provided written informed consent prior to study procedures.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Qualified researchers may request data from Amgen clinical studies. Complete details are available at\n                      \n                      .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: TT, YO, SK, MY, NU, WZ, MP, MM. Patient data collection: TT, YO, SK, SS, AM, SI, YT, MA, MY, NU, MM. Analysis and interpretation of data: TT, YO, SK, SS, AM, YT, MY, TH, MT, WZ, MP, MM.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}